Abstract Submission | Dementia Nursing Conference | Neuroscience Conference | Neuropharmacology Conference | Neurological Disorders Conference | Virtual Webinar

Theme: Tackling Dementia with Technology

Vascular Dementia 2021

Vascular Dementia 2021

On the behlaf of Vascular dementia 2021 committee, we are pleased to invite you to join the upcoming “13th International Conference on Vascular Dementia” to be held during on Oct 06-07, 2021 at London UK. The conference will be organized and focuses around the theme “Tackling Dementia with Technology’’

Vascular Dementia 2021 will permitting you to learn many new facts and techniques from hearing other’s displays, also you may converse with different academics from distinct universities, institutes and international locations you could have only heard or examine about. Also, presenting you with the possibility to fulfil and interact with scientists and researchers all over the world. Furthermore, we are hoping you all will join and take a touch time to share your revel in the direction Vascular Dementia 2021 additionally we're looking forward to welcoming you all to Online meeting/Webinar.

Why to attend ?

Vascular Dementia 2021 Conference is a unique forum to bring together worldwide distinguished academics in the field of Neuroscience and Neurology, Nutrition, Researchers, Public health professionals, Scientists, Academic scientists, Industry researchers, Scholars to exchange about state of the Research and Development.

Conference Opportunities are:

For Researchers and Faculty Members:

Speaker Presentations
Poster Display
Symposium hosting (team members 4-5)
Workshop organizing

For Students and Research Scholars:

Poster Competition(winner will get award)
Young Researcher Forum
Student Attending
Student Group Registrations

For Universities, Associations & Societies:

Association Partnering
Collaboration Proposals
Academic Partnering

For Business Delegates:

Symposium hosting
Book Launch event
Networking opportunities (good)
Audience participation (only interested)

For Product Manufacturers:

Exhibitor , Vendor Booths
Sponsorships opportunities
Product launch Workshop organizing
Scientific Partnering
Marketing and Networking with clients

Benefits

Best Poster Award(winner will get award)
Outstanding Young Researcher Award(YRA)
Group Registration benefits
Keynote sessions by the eminent researchers
Top Industries Representations

Target Audience:

Directors/Managers/CEO’s
Presidents & Vice Presidents Medical Colleges
Research faculty
Academic Scientists
Students group
Diagnostic laboratory professionals
Business Entrepreneurs
Neurologists
Neurosurgeons
Neurology doctors
Scientists and professors
Neuro research scholars
Industry professionals
Brand Manufacturers/ Marketers of Consumer Products

Track 1: Alzheimer’s Disease

Dementia may be a term that describes a good range of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities. and dementia is not a selected disease.. Vascular dementia, which occurs after a stroke, is that second commonest dementia type. But there are many other conditions that can will cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. Dementia is a syndrome that involves severe loss of cognitive abilities as a result of disease or injury. Dementia caused by traumatic brain injury is often static, whereas dementia caused by neurodegenerative disorders, like Alzheimer's disease

Primary mental health care and nursing
Novel therapeutics technology
Novel therapeutics strategies for Dementia
Mixed dementia
Frontotemporal dementia

Related Conference: Alzheimer’s Disease & Dementia, November 14-15, 2019, Paris, France | Alzheimer's Disease and Dementia, September 23-25, 2014 Valencia, Spain | Alzheimer’s Disease & Dementia,August 31-September 02, 2015 Toronto, Canada | Vascular Dementia, June 30 - July 02, 2016 Valencia, Spain | Dementia Conference, September 02-13, 2019 London, UK | Alzheimer’s Disease & Dementia,October 16-18, 2017 Rome, Italy

Track 2: Vascular Dementia

Vascular dementia is the broad term for dementia associated with problems of circulation of blood to the brain. There are a number of different types of Vascular dementia. Two of the most common are Multi-infarct dementia and Binswanger's disease. The multi-infarct dementia (MID) and vascular intellectual impedance is dementia caused by issues in the supply of blood to the mind, normally a progression of minor strokes. People with vascular dementia give dynamic subjective hindrance, intensely or sub acutely as in mellow psychological debilitation, every now and again step-wise, after various cerebrovascular occasions (strokes). A few people may seem to enhance amongst occasions and decrease after more noiseless strokes. A quickly decaying condition may prompt demise from a stroke, coronary illness, or infection. Vascular dementia can be caused by ischemic or hemorrhagic infarcts influencing numerous mind regions, including the foremost cerebral supply route domain, the parietal projections, or the cingulate gurus.

Vascular dementia prognosis
Young onset dementia
Multi-infarct dementia
Parkinson dementia
Advences in vascular dementia therapy

Track 3: Dementia Nursing

Caregivers of dementia patients go to understand dementia in order that they will understand what the patient is going through. They need to know about underlying diseases, and how these can affect the progress of dementia. They also need to know what kind of behavior to expect. Understanding these helps them plan for his or her caregiving and to deal with things effectively , and with less stress.

Dementia nursing care plan
Music therapy in dementia
Physiotherapy for dementia
Clinical features of dementia
Therapeutic interventions in dementia

Track 4: Recent Advancement in Treating Dementia

Two drugs, gantenerumab ,and solanezumab are currently being tested. Both are designed to help remove excess beta-amyloid in the brain. The brain changes of people with this form of Alzheimer's are very similar to the brain changes of those with the more common sporadic form of Alzheimer's disease.

Medication side effects
Excess use of alcohol
Thyroid problems
Vitamin deficiencies

Keyword: dementia conference| Neurology conference| Dementia congress|

Track 5: Neurological Disorders

Neurological disorders are medically defined as disorders that affect the brain as well as the nerves found throughout the human body,and the spinal cord. Structural, biochemical or electrical abnormalities in the brain, spinal cord,or other nerves can result in a range of .symptoms.

Extracellular recording
Deep brain stimulation
Stimulus artifact
Template
Digital subtraction

Track 6: Stroke Rehabilitation and Brain Haemorrhage

A physical therapy program may include exercises to strengthen muscles, improve coordination, and regain range of motion; and constraint-induced therapy, in which an unaffected limb is immobilized, causing the person to use the affected limb to regain movement and function A brain hemorrhage is bleeding in or around the brain. It is a form of stroke.In the many Causes of brain hemorrhage include high blood pressure (hypertension), abnormally weak or dilated (aneurysm) blood vessels that leak, drug abuse, and trauma

epidural hematoma.
subdural hematoma.
subarachnoid hemorrhage

Track 7: Brain Tumor and Neuro oncology

A brain tumor is a mass or growth of abnormal cells in your brain. Many different types of brain tumors exist. Some brain tumors are noncancerous (benign), and some brain tumors are cancerous (malignant). That is a branch of Medical Sciences majorly deals with Neuro tumors. Deals with Studies related to Brain and Spinal cord neoplasms. Neuro-oncology and Pediatric Neuro-oncology are the two different Concepts that differentiate the determining methodology of Neuro tumors. Neuro-oncology mainly includes especially related topics like Radiation therapy, Neurosurgery, Neuroimaging, social, Psychological, Neuropathology and psychiatric aspects

Signs and symptoms of dementia
Spine Cancer and Spine Cancer Treatment
Glioblastoma
Meningioma
Brain Stem Tumors
Malignant Brain Cancers and Brain Metastasis
Pediatric Neuro Oncology
Astrocytoma
Neurotoxicity

Track 8: Neuropsychiatry

A neuropsychiatrist is a psychiatrist specializing in the diagnosis and treatment of disorders affecting the brain which cause behavioral, psychological and psychiatric symptoms.

seizures.
attention deficit disorders.
cognitive deficit disorders.
palsies.
uncontrolled anger.
migraine headaches.
addictions.
eating disorders

Track 9: Anxiety & Depression

Depression and anxiety disorders are different, but people with depression often experience symptoms similar to those of an anxiety disorder, such as nervousness, irritability, and problems sleeping and concentrating. But each disorder has its own causes and its own emotional and behavioral symptoms.

Keywords 9:Dementia Conferences | Neurology Conference |Neuroscience Conferences

Track 10: Treatment for Dementia

Treatment of dementia begins with the treatment of the underlying disease, where possible. The underlying causes of nutritional, hormonal, tumour-caused or drug-related dementia may be reversible to some extent. For many other diseases, such as Alzheimer's disease (AD), no cure has yet been discovered. However, improvement of cognitive and behavioural symptoms can be achieved through a combination of appropriate medications and other treatments, including psychotherapy.

Dementia nursing care plan
Music therapy in dementia
Physiotherapy for dementia
linical features of dementia
Therapeutic interventions in dementia

Track 11: Bioinformatics Approach for Dementia

Early detection of patients at risk of developing AD is of central importance. Blood-based genetic signatures can serve as early detection and as population-based screening tools. Alzheimer’s disease (AD) is a serious degenerative brain disease and the most common cause of dementia. The current available drugs for AD provide symptomatic benefit, but there is no effective drug to cure the disease. The emergence of large-scale genomic, pharmacological data provides new opportunities for drug discovery and drug repositioning as a promising strategy in searching novel drug for AD.Alzheimer’s disease is a progressive neurodegenerative disorder characterized by deposition of amyloid plaques composed of aggregated amyloid beta plaques, and neurofibrillary tangles composed of hyperphosphorylated tau that leads to synaptic defects resulting in neuritic dystrophy and neuronal death.

Proteomics in Dementia
Transcriptomics in Dementia
Epigenomics of Dementia
Data Mining Methods for Diagnosis of Dementia

Track 12: Neurodegenerative Diseases

Neurodegenerative disease is an umbrella term for a range of conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Examples of neurodegenerative diseases include Parkinson’s, Alzheimer’s, and Huntington’s disease.

Epilepsy/Seizures
Spinocerebellar ataxia (SCA)
Huntington’s disease (HD)
Motor neurone diseases (MND)
Prion disease
Parkinson’s disease (PD) and PD-related disorders
Traumatic brain injury: TBI
Brain Injury
Stroke
Spinal muscular atrophy (SMA)

Track 13: Neurology and Neurosurgery

While neurologists and neurosurgeons diagnose and treat diseases of the nervous system, neurologists do not do any surgery. Neurologists focus on identifying specific diagnostic neurological conditions that can be corrected with other drugs or therapies or that require strict care

Microvascular decompression
Peripheral nerve surgery
Brain tumour excision
Functional neurosurgery
Pituitary surgery
Cervical spine surgery

Track 14: Neuropharmacology

Neuropharmacology is an extremely wide locale of science that includes numerous parts of the sensory system from single neuron control to whole ranges of the cerebrum, spinal line, and fringe nerves. To better comprehend the premise behind medication advancement, one should first see how neurons speak with each other. This article will concentrate on both behavioral and atomic neuropharmacology; the real receptors, particle channels, and neurotransmitters controlled through medication activity and how individuals with a neurological issue advantage from this medication activity.

Neuroscience and neuropharmacology
Neurochemical interaction
Anti-dementia drugs
Novel drug target for the treatment of dementia
Novel therapeutics molecule

Track 15: Psychiatry Mental health disorders

A psychiatric disorder is a mental illness diagnosed by a mental health professional that greatly disturbs your thinking, moods, and/or behavior and seriously increases your risk of disability, pain, death, or loss of freedom.¹In addition, your symptoms must be more severe than expected response to an upsetting event, such as normal grief after the loss of a loved one. an upsetting event, such as normal grief after the loss of a loved one

Track 16: Neuroimaging Biomarkers

Neuroimaging biomarkers use brain imaging techniques in order to image the morphology (e.g., MRI), the function (e.g. fMRI), the microenvironment (e.g., perfusion MRI), the metabolism (e.g., PET-FDG), or the molecular content (e.g., MR spectroscopy) of the brain and its lesions (Boland. 2014).Neuroimaging biomarkers of Alzheimer's Disease include measurement of beta-amyloid deposition with amyloid PET, of brain metabolism with FDG-PET, of brain and hippocampal atrophy with MRI (Bateman et al. 2012). Read more about neuroimaging biomarkers for Alzheimer's disease.

Diagnostic biomarkers
Susceptibility/risk biomarker

Track 17: Vascular Dementia and Central Nervous System

Vascular dementia is the broad term for dementia associated with problems of circulation of blood to the brain. There are a number of different types of Vascular dementia. Two of the most common are Multi-infarct dementia and Binswanger's disease The central nervous system (CNS) controls most functions of the body and mind. It consists of two parts: the brain and the spinal cord. The brain is the center of our thoughts, the interpreter of our external environment, and the origin of control over body movement.

autonomic nerves
motor nerves
sensory nerves

Track 18: Alzheimer’s Clinical Trials and Studies

Clinical trials are research studies conducted with human volunteers to determine whether treatments are safe and effective. Without clinical research and the help of participants, there can be no treatments, prevention or cure for Alzheimer's disease.

Interventional trials
Prevention trials
Observational trials

Track 19: Diagnostic Alzheimer

To diagnose Alzheimer's dementia, your primary doctor, a doctor trained in brain conditions (neurologist) or a doctor trained to treat older adults (geriatrician) will review your medical history, medication history and your symptoms. Your doctor will also conduct several tests.

Laboratory tests
Brain scans
Psychiatric evaluation
Genetic tests

Track:20: Molecular Genetics and Biology of Dementia

Like several other adult onset neurodegenerative diseases, Alzheimer's disease is a multifactorial illness with both genetic and non-genetic causes. Recent genetic studies have identified four genes associated with inherited risk for AD (presenilin 1, presenilin 2, amyloid precursor protein, and apolipoprotein E). These genes account for about half of the total genetic risk for Alzheimer's disease.

DNA techniques

The treatment for global market in evaluation of syndromes for vascular dementia, with the movement disorders values are of range 10.5 billion in 2011 that reach $11.1 billion in 2012. Total market value that is expected to reach $16.7 billion in 2017 with raise at a five-year compound annual growth rate (CAGR) of 8.5%.

From every corner of the world, someone develops dementia every 3 seconds. This was an estimated value at 46.8 million people worldwide living with dementia in 2015 and the number is expected to be close to 50 million people in 2017. This number may double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Mostly it is observed too be increased in developing countries. For now, 58% of people with dementia are living in low and middle income countries, may be, by 2050 this can rise to 68%.

Worldwide results of current meta-analysis reveal 44 million people (worldwide) suffered with Vascular dementia during 2010 and expected to double every 20 years, to the number 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58 per cent of all people with low or middle incomes were with dementia lived in countries. This proportion anticipated in increase to 63 per cent in 2030 and 71 per cent in 2050.The values are expected to double by 2030 and triple by 2050 to 115 million.The survey reveals in United States, an estimate of many as five million people age 65 and older suffer from Alzheimer’s disease.

Vascular Dementia is most widely considered to be the second common cause of Alzheimer's disease, accounting for 10 % of cases. Many experts believe vascular dementia remains less diagnosed for Alzheimer's disease, even the disease is common.Alzheimer's Research UK at present funds 150 research projects across UK and focusing on developing stages which has been committed nearly £40million to dementia research.Their research focus is on improvement of the quality of life already living with Alzheimer’s disease and also other forms of dementia.

Vascular Dementia 2019

The "11th International conference on Vascular Dementia" hosted by Conference Series llc LTD took place at Amsterdam, Netherlands during February 15-16, 2019.
Active participation and generous response were received from the Organizing Committee Members, Editorial Board Members of Conference Series llc LTD Journals as well as from eminent scientists, talented researchers and young student community.
Researchers and students who attended from different parts of the world have made the conference one of the most successful and productive events in 2019 from Conference Series llc LTD.
The conference was marked by the presence of renowned scientists, talented young researchers, students and business delegates driving the three days event into the path of success with thought-provoking keynote and plenary presentations highlighting the theme “ Decoding Dementia and Alzheimer” Conference Series llc LTD has taken the privilege of felicitating Vascular Dementia congress 2019 Conference Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this event.
Conference Series llc LTD, on behalf of the conference sponsor, appreciates all the participants who put their efforts for this event and sincerely wishes them success in future endeavours.
The esteemed guests, Keynote speakers, well-known researchers, and delegates shared their innovative research and vast experience through their fabulous presentations at the podium of grand Vascular Dementia 2019 Conference.
We are glad to inform that all accepted abstracts for the conference have been indexed in Conference Series llc LTD “Journal of Alzheimer’s Disease & Parkinsonism” as a special issue.
We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums.
We sincerely thank the Organizing Committee Members for their gracious presence, support and assistance towards the success of Vascular Dementia 2019.
With the unique feedbacks from the conference, Conference Series llc LTD would like to announce the commencement of the 13th World Congress on Vascular Dementia and Neurodegenerative Diseases on June 28-29,2021 (webinar).
Let us meet again @Vascular Dementia 2021

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 06-07, 2021
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

Media Partners

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

13^th International Conference on Vascular Dementia October 06-07, 2021 London, UK

Recommended Global Neuroscience Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links